Technology

ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $68.88, marking a -0.17% move from the previous day. This change lagged the S&P 500's 0.16% gain on the day. At the same time, the Dow added 0.42%, and the tech-heavy Nasdaq gained 0.03%.

Prior to today's trading, shares of the drugmaker had gained 7.06% over the past month. This has outpaced the Medical sector's loss of 8.18% and the S&P 500's gain of 2.89% in that time.

Wall Street will be looking for positivity from ANIP as it approaches its next earnings report date. The company is expected to report EPS of $1.03, down 21.97% from the prior-year quarter.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $5.97 per share and revenue of $248 million. These totals would mark changes of +17.75% and +23.03%, respectively, from last year.

Investors might also notice recent changes to analyst estimates for ANIP. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.92% higher. ANIP is currently a Zacks Rank #1 (Strong Buy).

Looking at its valuation, ANIP is holding a Forward P/E ratio of 11.57. Its industry sports an average Forward P/E of 19.86, so we one might conclude that ANIP is trading at a discount comparatively.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 46, putting it in the top 19% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Click to get this free report

ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.